CALABASAS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who […]

CALABASAS, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, will be featured on Health Uncensored hosted by Dr. Drew Pinsky. The episode is scheduled to air on the Lifetime Network, available to approximately 63 million television households […]

CALABASAS, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has authorized the Company to proceed with Phase IIa/IIb of its NEO212-01 clinical […]